On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...